Cyteir Therapeutics, Inc. (CYT)
$3.05
+0.02
(+0.66%)▲
Market is closed - opens 8 PM, 04 Dec 2023
Performance
- $3.03$3.07$3.05
0.82%
Downside
Day's Volatility :1.31%
Upside
0.49%
- $1.13$3.10$3.05
62.95%
Downside
52 Weeks Volatility :63.55%
Upside
1.61%
Returns
| Period | Cyteir Therapeutics, Inc. | |
|---|---|---|
3 Months | 10.91% | |
6 Months | 36.77% | |
1 Year | 114.79% | |
3 Years | -83.85% |
Highlights
Market Capitalization | 110.2M |
Book Value | $3.47 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.93 |
Wall Street Target Price | 3.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -14.5% |
Return On Equity TTM | -23.81% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -16.6M |
EBITDA | -33.4M |
Diluted Eps TTM | -0.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.08 |
EPS Estimate Next Year | -0.87 |
EPS Estimate Current Quarter | -0.25 |
EPS Estimate Next Quarter | -0.25 |
Analyst Recommendation
Sell
0
0%Buy
37%Hold
62%Sell
Based on 8 Wall street analysts offering stock ratings for Cyteir Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
- Current
- 1M Ago
- 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
5
6
6
Analyst Forecast
What analysts predicted
Downside of 1.64%
Current $3.05
Target $3.00
Technicals Summary
Sell
Neutral
Buy
Cyteir Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cyteir Therapeutics, Inc. | 2.01% | 36.77% | 114.79% | -83.85% | -83.85% |
 Moderna, Inc. | 12.07% | -38.83% | -56.22% | -44.17% | 329.19% |
 Regeneron Pharmaceuticals, Inc. | -0.48% | 10.12% | 6.32% | 61.32% | 112.97% |
 Novo Nordisk A/s | -0.53% | 27.78% | 58.23% | 194.69% | 336.14% |
 Seagen, Inc. | -0.96% | 8.88% | 73.78% | 20.15% | 232.63% |
 Vertex Pharmaceuticals Incorporated | -6.74% | 5.21% | 9.27% | 54.9% | 90.18% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cyteir Therapeutics, Inc. | 0.28 | NA | NA | -1.08 | -0.24 | -0.14 | 0.0 | 3.47 |
Moderna, Inc. | 24.73 | NA | 0.0 | -11.52 | -0.22 | -0.07 | 0.0 | 35.32 |
Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
Novo Nordisk A/s | 43.04 | 43.04 | 2.03 | 2.62 | 0.89 | 0.22 | 0.01 | 20.77 |
Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
Vertex Pharmaceuticals Incorporated | 26.52 | 26.52 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cyteir Therapeutics, Inc. | Sell | $110.2M | -83.85% | 0.28 | 0.0% |
Moderna, Inc. | Buy | $29.6B | 329.19% | 24.73 | -38.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 112.97% | 22.78 | 30.47% |
Novo Nordisk A/s | Buy | $470.4B | 336.14% | 43.04 | 35.11% |
Seagen, Inc. | Hold | $40.0B | 232.63% | NA | -32.61% |
Vertex Pharmaceuticals Incorporated | Buy | $91.0B | 90.18% | 26.52 | 35.94% |
Institutional Holdings
BML Capital Management LLC
8.98%Newtyn Management LLC
6.91%OUP Management Co., LLC
6.80%Anson Funds Management LP
3.66%VR Advisory Services Ltd
2.97%FMR Inc
2.29%
Company Information
through a unique cancer treatment approach, cyteir therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.
Organization | Cyteir Therapeutics, Inc. |
Employees | 46 |
CEO | Mr. Joseph S. Zakrzewski |
Industry | Services |
